Xounta Athina Hepatologist

Fellowship in Societies, Membership in Journal Editorial Committees

• Member of the Hellenic Αssociation for the Study of Liver

Work Experience

• 2020 – : Consultant, “Hygeia” Hospital

• 2009 – 2020:  Director of NHS, 4th Dep. of Internal Medicine,

  National  and Kapodistrian  University of Athens, University Hospital “ATTIKON”

• 2002-2009:  Associate Director NHS, 4th Dep. of Internal Medicine

  National  and Kapodistrian University of Athens, University Hospital “ATTIKON”

• 2002 – 2020:  Head of Hepatology Department – follow-up of over 4000 registered patients

• 1997 – 2002: Senior Registrar A of NHS, 1rst Dep. of Internal Medicine, Hepatology Clinic, General Hospital of  WEST ATTICA “AGIA VARVARA”

• 1996 -1997: 1rst Dep. of Internal Medicine, Thriasio General Hospital – Organization and Operation of Hepatology Department

• 1990 – 1996:  Registrar B of NHS Internal Medicine, Ippokration G.P. Athens Hospital

Clinical & Research Interest

Clinical Interest:

• Instructor and head of the Educational Program With Subject: Liver Diseases, Cirrhosis and Infections, Portal Hypertension, HBV Hepatitis, HCV and HIV co-Infection, Metabolic Diseases, NAFLD, NASH,

• Alcoholic Liver disease, HCC, Liver and Pregnancy –  4th Dep. Of

• Internal Medicine, National  and Kapodistrian  University of Athens, University Hospital “ATTIKON”

• Participation in the Training Program for residents in Internal

• Medicine – 4th Dep. of Internal Medicine, National and Kapodistrian  University of Athens, University Hospital “ATTIKON”

• Trainee of Medical students – 4^th Dep of Medicine, National and Kapodistrian University of Athens, University Hospital “ATTIKON

• Liver Diseases in Pregnancy – Participation in PostGraduate Program of the 2nd Obstetrics and Gynecology Clinic, National  and Kapodistrian  University of Athens, University Hospital ATTIKON

Research Interest:

• Participation in epidemiological research for Hepatitis A, B and C in municipalities of West Attica

• Phase 3 study for the administration of Antiviral Therapy with DAAs in patients with Hepatitis C and Renal Insufficiency

• Retrospective observation of patients with Hepatitis C treated with oral antivirals (DAAs)

• Epidemiological study of IVDU patients with Hepatitis C

• Retrospective study of Hepatitis C patients receiving ELB / GRZ – Efficacy

• Participation in the ARISTOTLE HCV-HIV Program in intravenous drug users, National Kapodistrian University of Athens

Recent Publications

• A cost of illness analysis of Hepatocellular Carcinoma for the Greek healthcare setting. Athanasakis K, Pliarchopoulou F, Naoum V, Psarrakis C, Tziolos N, Marantos T, Damoulari C, Chounta A .Gastroenterol Hepatol Bed Bench. 2020 Summer 13(3):219-222.

• Association of antiviral therapy with reduced disease progression in chronic Hepatitis B patients: Results from a nation-wide cohort study. Vourli G, Papatheodoridis G, Raptopoulou M, Dalekos GN, Chounta A, Nikolopoulou G, Zouboulis-Vafeiadis I, Manesis E, Kitis G, Gogos C, Ketikoglou I, Hatzis G, Vasilialdis T, Karatapanis S, Mimidis K, Drakoulis C, Touloumi G, The Hepnet-Greece. 2016 Jul-Sep 20(3):214-221.

• Sfrp5 associates with beta-cell function in humans. Carstensen-Kirberg M, Hatziagelaki E, Tsiavou A,Chounta A, Nowotny P, Pacini G, Dimitriadis G, Roden M, Herder Eur J Clin Invest. 2016 Jun;46(6):535-43.

• Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma. Chounta A, Ellinas C, Tzanetakou V, Pliarhopoulou F, Mplani V, Oikonomou A, Leventogiannis K, Giamarellos-Bourboulis Liver Int. 2015 Feb;35(2):601-7.

• Serum Chemerin Concentrations Associate with Beta-Cell Function, but Not with Insulin Resistance in Individuals with Non-Alcoholic Fatty Liver Disease (NAFLD) .Hatziagelaki E, Herder C, Tsiavou A, Teichert T,Chounta A, Nowotny P, Pacini G, Dimitriadis G, Roden M .PLoS One. 2015 May 1;10(5):

• Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study. Anagnostou O, Manolakopoulos S, Bakoyannis G, Papatheodoridis G, Zisouli A, Raptopoulou-Gigi M, Manesis E, Ketikoglou I, Dalekos G, Gogos C, Vassiliadis T, Tzourmakliotis D, Karatapanis S, Kanatakis S, Zoumpoulis -, Hounta A, Koutsounas S, Giannoulis G, Tassopoulos N, Touloumi G. 2014 Jan;18(1):57-64.

• Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. Manesis EK, Vourli G, Dalekos G, Vasiliadis T, Manolaki N, Hounta A, Koutsounas S, Vafiadis I, Nikolopoulou G, Giannoulis G, Germanidis G, Papatheodoridis G, Touloumi G. J Hepatol. 2013 Nov;59(5):949-56.

• Predictors of impaired glucose regulation in patients with non-alcoholic fatty liver disease.Hatziagelaki E, Karageorgopoulos DE, Chounta A, Tsiavou A, Falagas ME, Dimitriadis G.Exp Diabetes Res. 2012;2012:351974.

• Cholestatic liver injury after glimepiride therapy. Chounta A, Zouridakis S, Ellinas C, Tsiodras S, Zoumpouli C, Kopanakis S, Giamarellou HJ Hepatol. 2005 Jun;42(6):944-6.

• Sibutramine use associated with reversible hepatotoxicity.Chounta A, Tsiodras S, Zouridakis S, Doumas M, Giamarellou HAnn Intern Med. 2005 Nov 15;143(10):763-4